Search company, investor...
Magellan Biosciences company logo

Magellan Biosciences

magellanbio.com

Founded Year

2004

Stage

Acquired | Acquired

Total Raised

$34M

About Magellan Biosciences

Magellan Diagnostics is a medical device company. The company develops and manufactures point-of-care systems, clinical laboratory instruments, and analytical laboratory services focused on lead testing.

Headquarters Location

101 Billerica Ave Building 4

North Billerica, Massachusetts, 01862,

United States

978-856-2345

Missing: Magellan Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Magellan Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Magellan Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Magellan Biosciences is included in 4 Expert Collections, including Medical Devices.

M

Medical Devices

8,605 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

702 items

Companies developing technology to facilitate near-patient and point-of-care (POC) in vitro diagnostic testing. Companies tagged as #NearPatient&POCTesting

H

Health IT

7,901 items

C

Clinical Encounter Tech

625 items

Magellan Biosciences Patents

Magellan Biosciences has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/30/2010

7/31/2012

Quantum mechanics, Gas technologies, Industrial gases, Quantum measurement, Lead poisoning

Grant

Application Date

9/30/2010

Grant Date

7/31/2012

Title

Related Topics

Quantum mechanics, Gas technologies, Industrial gases, Quantum measurement, Lead poisoning

Status

Grant

Latest Magellan Biosciences News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Meridian Bioscience, Inc. - VIVO

Dec 12, 2017

Share this article NEW YORK, Dec. 12, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:   VIVO ). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether Meridian and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On March 24, 2016, Meridian announced the acquisition of Magellan Biosciences, Inc. and its wholly-owned subsidiary Magellan Diagnostics, Inc. (together "Magellan"). Magellan provides point-of-care lead testing systems for the testing of blood to diagnose lead poisoning in children and adults. On May 17, 2017, the U.S. Food and Drug Administration ("FDA") issued a press release "warning Americans that certain lead tests manufactured by Magellan Diagnostics may provide inaccurate results. "  On this news, Meridian's share price fell $1.30, or 8.81%, to close at $13.45 on May 17, 2017. On July 13, 2017, the FDA announced that it had observed several potential violations of federal law during a recent inspection of Magellan's facility in North Billerica, Massachusetts. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com . CONTACT:

Magellan Biosciences Frequently Asked Questions (FAQ)

  • When was Magellan Biosciences founded?

    Magellan Biosciences was founded in 2004.

  • Where is Magellan Biosciences's headquarters?

    Magellan Biosciences's headquarters is located at 101 Billerica Ave, North Billerica.

  • What is Magellan Biosciences's latest funding round?

    Magellan Biosciences's latest funding round is Acquired.

  • How much did Magellan Biosciences raise?

    Magellan Biosciences raised a total of $34M.

  • Who are the investors of Magellan Biosciences?

    Investors of Magellan Biosciences include Meridian , Boston Community Capital, KBL Healthcare Ventures, Ampersand Capital Partners, Abingworth and 5 more.

  • Who are Magellan Biosciences's competitors?

    Competitors of Magellan Biosciences include Huron Digital Pathology, LineaGen Research, BioMarker Strategies, Cardiac Science Corporation, Paragon Medical and 13 more.

Compare Magellan Biosciences to Competitors

N
Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

E
Expression Diagnostics

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.

P
Prion Diagnostica

Develop and introduce highly products or systems in selected fields of veterinary and human medicine for: Diagnostic Survey, Risk Watching, Safety controls. This company offers DNA testing for traceability purposes in beef, sheep and swine, and also genetic testing for disease resistance in sheep.

B
Beacon Analytical Systems

Beacon Develops immunodiagnostic kits for environmental & food/feed testing markets

K
Kjaya

Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.

Mediracer Logo
Mediracer

Mediracer Specialises In Medical Technology. The company's Core Business Is The Development, Manufacture And Global Sale Of Point Of Care (poc) Diagnostic Testing Equipment For Diseases Of The Peripheral Nervous System.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.